FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763817136> ?p ?o ?g. }

• W2763817136 endingPage "v184" @default.
• W2763817136 startingPage "v183" @default.
• W2763817136 abstract "Background: CRC cells evade EGFR blockade by several mechanisms of acquired resistance, mainly mutations in RAS, EGFR ECD, HER2 and MET. ctDNA is shed into the bloodstream by tumor cells and can be effectively used to track tumor heterogeneity and to evaluate acquired mutations at tumor progression. Methods: We included mCRC pts treated in a phase II study of FOLFIRI + panitumumab in irinotecan-refractory mCRC. ctDNA was collected at the end of treatment, processed with the Oncomine colon ctDNA Assay, and sequenced in the PGM Ion Torrent NGS System. The detectable cutoff mutation was 0.1%. Subclonal mutations were defined as mutations with mutant allele fraction (MAF) ≤ 50% of the greatest somatic MAF in the sample. Baseline mutations were analyzed in tumor tissue by dPCR. Results: ctDNA from 16 pts was analyzed. Clinical characteristics of pts were 69% male; median age 61.5 years; 75% left vs 25% right colon. At least one mutation was detected in 94% of pts (15/16); median mutations per sample was 2.5 (range 1 -13). The frequency of detected mutations was: 13 TP53, 3 APC, 1 CTNNB1, 15 KRAS, 8 NRAS, 7 EGFR, 4 BRAF, 4 PIK3CA, 4 MAP2K1, 1 GNAS, 1SMAD4. While TP53, APC, PIK3CA and BRAF were most likely to be clonal, EGFR, MAP2K1, RAS were generally subclonal. All EGFR ECD mutations emerged in the left colon and all co-existed with RAS mutations plus at least one additional acquired mutation (median 6, range 3-11). RAS/BRAF mutations emerged in 100% and 66% of right and left colon respectively, and co-existed with other acquired mutations in 72% of cases (median 3, range 1-11) Best response was: PR 8 pts, SD 6 pts and PD 2. In both pts with PD only one acquired mutation was detected at progression (PIK3CA and KRAS respectively), and both mutations were detected in the matching pre-treatment tissue and plasma sample at low MAF. Pts follow-up is ongoing, correlation between mutational profile and response to treatment will be presented. Conclusions: ctDNA analysis captured intrapatient heterogeneity that developed as a result of EGFR inhibition. All EGFR ECD mutations emerged in the left colon and always co-existed with several other mechanisms of acquired resistance, reflecting genomic complexity. Clinical trial identification: NCT01704703 Legal entity responsible for the study: Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) Funding: Public funding from the Spanish Ministry of Health, Social Policy and Equality. (Trial Ref: EC11-050) Disclosure: J.M. Viéitez: Consultant or advisory relationship, research funding and honoraria: Amgen. M. Valladares-Ayerbes: Consultant or advisory relationship and honoraria: Roche, Amgen, Merck Serono. E. Aranda Aguilar: Honoraria for advisory role from Amgen, Bayer, Celgene, Merck, Roche, Sanofi. All other authors have declared no conflicts of interest." @default.
• W2763817136 created "2017-10-20" @default.
• W2763817136 creator A5001410842 @default.
• W2763817136 creator A5011285961 @default.
• W2763817136 creator A5011994043 @default.
• W2763817136 creator A5019330308 @default.
• W2763817136 creator A5029623776 @default.
• W2763817136 creator A5030215661 @default.
• W2763817136 creator A5035175323 @default.
• W2763817136 creator A5036172060 @default.
• W2763817136 creator A5038693148 @default.
• W2763817136 creator A5042950398 @default.
• W2763817136 creator A5044467628 @default.
• W2763817136 creator A5048085062 @default.
• W2763817136 creator A5058226032 @default.
• W2763817136 creator A5061538968 @default.
• W2763817136 creator A5083616708 @default.
• W2763817136 creator A5090464803 @default.
• W2763817136 creator A5091612757 @default.
• W2763817136 date "2017-09-01" @default.
• W2763817136 modified "2023-10-18" @default.
• W2763817136 title "Circulating tumor (ct) DNA captures intrapatient heterogeneity in metastatic colorectal (mCRC) patients (pts) progressing to FOLFIRI+panitumumab" @default.
• W2763817136 doi "https://doi.org/10.1093/annonc/mdx393.068" @default.
• W2763817136 hasPublicationYear "2017" @default.
• W2763817136 type Work @default.
• W2763817136 sameAs 2763817136 @default.
• W2763817136 citedByCount "0" @default.
• W2763817136 crossrefType "journal-article" @default.
• W2763817136 hasAuthorship W2763817136A5001410842 @default.
• W2763817136 hasAuthorship W2763817136A5011285961 @default.
• W2763817136 hasAuthorship W2763817136A5011994043 @default.
• W2763817136 hasAuthorship W2763817136A5019330308 @default.
• W2763817136 hasAuthorship W2763817136A5029623776 @default.
• W2763817136 hasAuthorship W2763817136A5030215661 @default.
• W2763817136 hasAuthorship W2763817136A5035175323 @default.
• W2763817136 hasAuthorship W2763817136A5036172060 @default.
• W2763817136 hasAuthorship W2763817136A5038693148 @default.
• W2763817136 hasAuthorship W2763817136A5042950398 @default.
• W2763817136 hasAuthorship W2763817136A5044467628 @default.
• W2763817136 hasAuthorship W2763817136A5048085062 @default.
• W2763817136 hasAuthorship W2763817136A5058226032 @default.
• W2763817136 hasAuthorship W2763817136A5061538968 @default.
• W2763817136 hasAuthorship W2763817136A5083616708 @default.
• W2763817136 hasAuthorship W2763817136A5090464803 @default.
• W2763817136 hasAuthorship W2763817136A5091612757 @default.
• W2763817136 hasBestOaLocation W27638171361 @default.
• W2763817136 hasConcept C104317684 @default.
• W2763817136 hasConcept C121608353 @default.
• W2763817136 hasConcept C126322002 @default.
• W2763817136 hasConcept C143998085 @default.
• W2763817136 hasConcept C21790070 @default.
• W2763817136 hasConcept C2776705615 @default.
• W2763817136 hasConcept C2778332735 @default.
• W2763817136 hasConcept C2780259306 @default.
• W2763817136 hasConcept C2781187634 @default.
• W2763817136 hasConcept C501734568 @default.
• W2763817136 hasConcept C502942594 @default.
• W2763817136 hasConcept C526805850 @default.
• W2763817136 hasConcept C54355233 @default.
• W2763817136 hasConcept C71924100 @default.
• W2763817136 hasConcept C74231797 @default.
• W2763817136 hasConcept C86803240 @default.
• W2763817136 hasConceptScore W2763817136C104317684 @default.
• W2763817136 hasConceptScore W2763817136C121608353 @default.
• W2763817136 hasConceptScore W2763817136C126322002 @default.
• W2763817136 hasConceptScore W2763817136C143998085 @default.
• W2763817136 hasConceptScore W2763817136C21790070 @default.
• W2763817136 hasConceptScore W2763817136C2776705615 @default.
• W2763817136 hasConceptScore W2763817136C2778332735 @default.
• W2763817136 hasConceptScore W2763817136C2780259306 @default.
• W2763817136 hasConceptScore W2763817136C2781187634 @default.
• W2763817136 hasConceptScore W2763817136C501734568 @default.
• W2763817136 hasConceptScore W2763817136C502942594 @default.
• W2763817136 hasConceptScore W2763817136C526805850 @default.
• W2763817136 hasConceptScore W2763817136C54355233 @default.
• W2763817136 hasConceptScore W2763817136C71924100 @default.
• W2763817136 hasConceptScore W2763817136C74231797 @default.
• W2763817136 hasConceptScore W2763817136C86803240 @default.
• W2763817136 hasLocation W27638171361 @default.
• W2763817136 hasOpenAccess W2763817136 @default.
• W2763817136 hasPrimaryLocation W27638171361 @default.
• W2763817136 hasRelatedWork W2071471252 @default.
• W2763817136 hasRelatedWork W2330256487 @default.
• W2763817136 hasRelatedWork W2587699801 @default.
• W2763817136 hasRelatedWork W2617055067 @default.
• W2763817136 hasRelatedWork W2762469620 @default.
• W2763817136 hasRelatedWork W2804383336 @default.
• W2763817136 hasRelatedWork W2921870665 @default.
• W2763817136 hasRelatedWork W3000288349 @default.
• W2763817136 hasRelatedWork W4220811422 @default.
• W2763817136 hasRelatedWork W4379282407 @default.
• W2763817136 hasVolume "28" @default.
• W2763817136 isParatext "false" @default.
• W2763817136 isRetracted "false" @default.
• W2763817136 magId "2763817136" @default.
• W2763817136 workType "article" @default.